GlassScriptPhysician profile
Marc F Goldstein
NPI 1093863334
$21,565.99
in general payments reported to CMS, 2019-2025
45 companies · $3,626 in 2025
The $3,626 reported for 2025 was more than what 80% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,130 · 2020: $2,395 · 2021: $1,748 · 2022: $2,981 · 2023: $2,808 · 2024: $3,878 · 2025: $3,626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,901 · Education: $396 · Consulting Fee: $14.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,900.99 |
| Education | $396.06 |
| Consulting Fee | $14.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $4,441.81 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $3,235.30 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Csl Behring | $1,813.20 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Regeneron Healthcare Solutions, INC. | $1,542.24 | 2019-2025 | Dupixent |
| Fff Enterprises, INC. | $1,500.00 | 2020 | |
| Optinose US, INC. | $1,223.42 | 2019-2025 | |
| Genzyme Corporation | $950.45 | 2019-2025 | |
| Genentech USA, INC. | $819.95 | 2019-2025 | Xolair |
| Pfizer INC. | $720.59 | 2021-2025 | |
| Kaleo, INC. | $712.35 | 2019-2024 | Auvi-Q |
| Amgen INC. | $701.90 | 2021-2025 | Tezspire, Tavneos |
| Biocryst US Sales Co., LLC | $643.37 | 2022-2025 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $634.08 | 2020-2025 | Cuvitru, Aralast, Takhzyro |
| Bio Products Laboratory USA, INC. | $361.03 | 2019-2023 | Coagadex, Gammaplex |
| Novartis Pharmaceuticals Corporation | $320.01 | 2019-2025 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.